

Clint T Allen

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/759173/clint-t-allen-publications-by-year.pdf>

Version: 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

91
papers

2,561
citations

31
h-index

48
g-index

112
ext. papers

3,377
ext. citations

6.7
avg, IF

5.2
L-index

#	Paper	IF	Citations
91	Determining if T cell antigens are naturally processed and presented on HLA class I molecules.. <i>BMC Immunology</i> , 2022 , 23, 5	3.7	0
90	Immune Landscape and Role of Immunotherapy in Treatment of HPV-Associated Head and Neck Squamous Cell Carcinoma (HNSCC). <i>Current Otorhinolaryngology Reports</i> , 2022 , 10, 96	0.5	
89	Cure of syngeneic carcinomas with targeted IL-12 through obligate reprogramming of lymphoid and myeloid immunity.. <i>JCI Insight</i> , 2022 , 7,	9.9	1
88	Trismus and voice change after starting tuberculosis treatment. <i>IDCases</i> , 2021 , 26, e01307	2	0
87	Myeloid-Derived Suppressive Cell Expansion Promotes Melanoma Growth and Autoimmunity by Inhibiting CD40/IL27 Regulation in Macrophages. <i>Cancer Research</i> , 2021 , 81, 5977-5990	10.1	2
86	How Enhancing Immunity to Low-Risk HPV Could Cure Recurrent Respiratory Papillomatosis. <i>Laryngoscope</i> , 2021 , 131, 2041-2047	3.6	1
85	Chimeric antigen receptor engineered NK cellular immunotherapy overcomes the selection of T-cell escape variant cancer cells 2021 , 9,		7
84	First-in-human phase I/II trial of PRGN-2009 vaccine as monotherapy or with bintrafusp alfa in patients with recurrent/metastatic (R/M) human papillomavirus (HPV)-associated cancers (HPVC) and as neoadjuvant/induction therapy in locoregionally advanced (LA) HPV oropharyngeal (OP) and sinonasal (SN) squamous cell cancer (SCC).. <i>Journal of Clinical Oncology</i> , 2021 , 39, TPS6092-TPS6092	2.2	2
83	Near-infrared photoimmunotherapy targeting human-EGFR in a mouse tumor model simulating current and future clinical trials. <i>EBioMedicine</i> , 2021 , 67, 103345	8.8	9
82	The REASON score: an epigenetic and clinicopathologic score to predict risk of poor survival in patients with early stage oral squamous cell carcinoma. <i>Biomarker Research</i> , 2021 , 9, 42	8	3
81	Preclinical study of a novel therapeutic vaccine for recurrent respiratory papillomatosis. <i>Npj Vaccines</i> , 2021 , 6, 86	9.5	0
80	Biologics for the Treatment of Recurrent Respiratory Papillomatosis. <i>Otolaryngologic Clinics of North America</i> , 2021 , 54, 769-777	2	1
79	Dual PD-L1 and TGF-b blockade in patients with recurrent respiratory papillomatosis 2021 , 9,		2
78	Somatic Mutations in UBA1 Define a Distinct Subset of Relapsing Polychondritis Patients With VEXAS. <i>Arthritis and Rheumatology</i> , 2021 , 73, 1886-1895	9.5	24
77	Immunotherapy for HPV Malignancies. <i>Seminars in Radiation Oncology</i> , 2021 , 31, 361-370	5.5	1
76	Brush swab as a noninvasive surrogate for tissue biopsies in epigenomic profiling of oral cancer.. <i>Biomarker Research</i> , 2021 , 9, 90	8	0
75	Comprehensive multiomic characterization of human papillomavirus-driven recurrent respiratory papillomatosis reveals distinct molecular subtypes.. <i>Communications Biology</i> , 2021 , 4, 1416	6.7	2

74	Defining Clinical Subgroups in Relapsing Polychondritis: A Prospective Observational Cohort Study. <i>Arthritis and Rheumatology</i> , 2020 , 72, 1396-1402	9.5	9
73	Mechanisms of resistance to T cell-based immunotherapy in head and neck cancer. <i>Head and Neck</i> , 2020 , 42, 2722-2733	4.2	7
72	PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations 2020 , 8,		40
71	Tumor control via targeting PD-L1 with chimeric antigen receptor modified NK cells. <i>ELife</i> , 2020 , 9,	8.9	19
70	Improving responses to immunotherapy in head and neck squamous cell carcinoma 2020 , 107-133		
69	ASTX660, an antagonist of cIAP1/2 and XIAP, increases antigen processing machinery and can enhance radiation-induced immunogenic cell death in preclinical models of head and neck cancer. <i>Oncolmunology</i> , 2020 , 9, 1710398	7.2	13
68	Neoadjuvant PD-1 Immune Checkpoint Blockade Reverses Functional Immunodominance among Tumor Antigen-Specific T Cells. <i>Clinical Cancer Research</i> , 2020 , 26, 679-689	12.9	19
67	Inhibition of MDSC Trafficking with SX-682, a CXCR1/2 Inhibitor, Enhances NK-Cell Immunotherapy in Head and Neck Cancer Models. <i>Clinical Cancer Research</i> , 2020 , 26, 1420-1431	12.9	67
66	Posterior Subglottic Mass in a Patient With a History of Rectal Adenocarcinoma and Lung Metastases. <i>JAMA Oncology</i> , 2020 , 6, 1967-1968	13.4	
65	Antigen processing and presentation in cancer immunotherapy 2020 , 8,		21
64	Host Immunity Following Near-Infrared Photoimmunotherapy Is Enhanced with PD-1 Checkpoint Blockade to Eradicate Established Antigenic Tumors. <i>Cancer Immunology Research</i> , 2019 , 7, 401-413	12.5	57
63	Direct and antibody-dependent cell-mediated cytotoxicity of head and neck squamous cell carcinoma cells by high-affinity natural killer cells. <i>Oral Oncology</i> , 2019 , 90, 38-44	4.4	14
62	Safety and clinical activity of PD-L1 blockade in patients with aggressive recurrent respiratory papillomatosis 2019 , 7, 119		15
61	How patients with an intact immune system develop head and neck cancer. <i>Oral Oncology</i> , 2019 , 92, 26-32	4.4	7
60	Enhancing direct cytotoxicity and response to immune checkpoint blockade following ionizing radiation with Wee1 kinase inhibition. <i>Oncolmunology</i> , 2019 , 8, e1638207	7.2	21
59	Dual Antagonist of cIAP/XIAP ASTX660 Sensitizes HPV and HPV Head and Neck Cancers to TNF α TRAIL, and Radiation Therapy. <i>Clinical Cancer Research</i> , 2019 , 25, 6463-6474	12.9	15
58	Inhibiting myeloid-derived suppressor cell trafficking enhances T cell immunotherapy. <i>JCI Insight</i> , 2019 , 4,	9.9	95
57	Galectin-1-driven T cell exclusion in the tumor endothelium promotes immunotherapy resistance. <i>Journal of Clinical Investigation</i> , 2019 , 129, 5553-5567	15.9	49

56	Sicca Syndrome Associated with Immune Checkpoint Inhibitor Therapy. <i>Oncologist</i> , 2019 , 24, 1259-1269	5.7	67
55	Semaphorin4D Inhibition Improves Response to Immune-Checkpoint Blockade via Attenuation of MDSC Recruitment and Function. <i>Cancer Immunology Research</i> , 2019 , 7, 282-291	12.5	24
54	Exploring the rationale for combining ionizing radiation and immune checkpoint blockade in head and neck cancer. <i>Head and Neck</i> , 2018 , 40, 1321-1334	4.2	9
53	Nanocomplex-based gene therapy promotes anti-tumor immunity through TP53- and STING-dependent mechanisms. <i>Oncolmmunology</i> , 2018 , 7, e1404216	7.2	13
52	The PD-1 and PD-L1 pathway in recurrent respiratory papillomatosis. <i>Laryngoscope</i> , 2018 , 128, E27-E32	3.6	24
51	Inhibition of WEE1 kinase and cell cycle checkpoint activation sensitizes head and neck cancers to natural killer cell therapies 2018 , 6, 59		29
50	WEE1 kinase inhibition reverses G2/M cell cycle checkpoint activation to sensitize cancer cells to immunotherapy. <i>Oncolmmunology</i> , 2018 , 7, e1488359	7.2	21
49	Antagonist of cIAP1/2 and XIAP enhances anti-tumor immunity when combined with radiation and PD-1 blockade in a syngeneic model of head and neck cancer. <i>Oncolmmunology</i> , 2018 , 7, e1471440	7.2	25
48	Cancer immunogenomic approach to neoantigen discovery in a checkpoint blockade responsive murine model of oral cavity squamous cell carcinoma. <i>Oncotarget</i> , 2018 , 9, 4109-4119	3.3	19
47	Inflammation and Head and Neck Squamous Cell Carcinoma. <i>Current Cancer Research</i> , 2018 , 353-364	0.2	
46	PD-1 blockade reverses adaptive immune resistance induced by high-dose hypofractionated but not low-dose daily fractionated radiation. <i>Oncolmmunology</i> , 2018 , 7, e1395996	7.2	57
45	Epigenetic priming of both tumor and NK cells augments antibody-dependent cellular cytotoxicity elicited by the anti-PD-L1 antibody avelumab against multiple carcinoma cell types. <i>Oncolmmunology</i> , 2018 , 7, e1466018	7.2	32
44	Evaluating the utility of serological testing in laryngotracheal stenosis. <i>Laryngoscope</i> , 2017 , 127, 1408-1412	3.1	4
43	Anti-PD-L1 Efficacy Can Be Enhanced by Inhibition of Myeloid-Derived Suppressor Cells with a Selective Inhibitor of PI3K. <i>Cancer Research</i> , 2017 , 77, 2607-2619	10.1	123
42	Laryngotracheal Stenosis: Risk Factors for Tracheostomy Dependence and Dilation Interval. <i>Otolaryngology - Head and Neck Surgery</i> , 2017 , 156, 321-328	5.5	41
41	Murray secretion scale and fiberoptic endoscopic evaluation of swallowing in predicting aspiration in dysphagic patients. <i>European Archives of Oto-Rhino-Laryngology</i> , 2017 , 274, 2513-2519	3.5	14
40	Induction of tumor regression by intratumoral STING agonists combined with anti-programmed death-L1 blocking antibody in a preclinical squamous cell carcinoma model. <i>Head and Neck</i> , 2017 , 39, 1086-1094	4.2	28
39	Resistance to CTLA-4 checkpoint inhibition reversed through selective elimination of granulocytic myeloid cells. <i>Oncotarget</i> , 2017 , 8, 55804-55820	3.3	58

38	Syngeneic Mouse Models of Oral Cancer Are Effectively Targeted by Anti-CD44-Based NIR-PIT. <i>Molecular Cancer Research</i> , 2017 , 15, 1667-1677	6.6	44
37	Cisplatin Alters Antitumor Immunity and Synergizes with PD-1/PD-L1 Inhibition in Head and Neck Squamous Cell Carcinoma. <i>Cancer Immunology Research</i> , 2017 , 5, 1141-1151	12.5	98
36	Dose-dependent enhancement of T-lymphocyte priming and CTL lysis following ionizing radiation in an engineered model of oral cancer. <i>Oral Oncology</i> , 2017 , 71, 87-94	4.4	16
35	Office-Based vs Traditional Operating Room Management of Recurrent Respiratory Papillomatosis: Impact of Patient Characteristics and Disease Severity. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2017 , 143, 55-59	3.9	12
34	Avoiding phagocytosis-related artifact in myeloid derived suppressor cell T-lymphocyte suppression assays. <i>Journal of Immunological Methods</i> , 2017 , 440, 12-18	2.5	12
33	Established T Cell-Inflamed Tumors Rejected after Adaptive Resistance Was Reversed by Combination STING Activation and PD-1 Pathway Blockade. <i>Cancer Immunology Research</i> , 2016 , 4, 1061-1071	12.5	78
32	Pools of programmed death-ligand within the oral cavity tumor microenvironment: Variable alteration by targeted therapies. <i>Head and Neck</i> , 2016 , 38, 1176-86	4.2	14
31	Anatomic Derkey Score Is Associated with Voice Handicap in Laryngeal Papillomatosis in Adults. <i>Otolaryngology - Head and Neck Surgery</i> , 2016 , 154, 689-92	5.5	13
30	Overcoming barriers to effective immunotherapy: MDSCs, TAMs, and Tregs as mediators of the immunosuppressive microenvironment in head and neck cancer. <i>Oral Oncology</i> , 2016 , 58, 59-70	4.4	78
29	Enhanced Tumor Control with Combination mTOR and PD-L1 Inhibition in Syngeneic Oral Cavity Cancers. <i>Cancer Immunology Research</i> , 2016 , 4, 611-20	12.5	50
28	CCR 20th anniversary commentary: Preclinical study of proteasome inhibitor bortezomib in head and neck cancer. <i>Clinical Cancer Research</i> , 2015 , 21, 942-3	12.9	7
27	A Submucosal True Vocal Fold Mass. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2015 , 141, 1025-6	3.9	1
26	Anti-Tumor Immunity in Head and Neck Cancer: Understanding the Evidence, How Tumors Escape and Immunotherapeutic Approaches. <i>Cancers</i> , 2015 , 7, 2397-414	6.6	51
25	Tracheal mass. Malignant melanoma metastatic to the trachea. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2015 , 141, 291-2	3.9	1
24	mTOR and MEK1/2 inhibition differentially modulate tumor growth and the immune microenvironment in syngeneic models of oral cavity cancer. <i>Oncotarget</i> , 2015 , 6, 36400-17	3.3	34
23	Immunohistochemical analysis of NF- κ B in human tumor tissue. <i>Methods in Molecular Biology</i> , 2015 , 1280, 459-68	1.4	
22	Risk stratification in endoscopic airway surgery: is inpatient observation necessary?. <i>American Journal of Otolaryngology - Head and Neck Medicine and Surgery</i> , 2014 , 35, 747-52	2.8	3
21	Hoarseness after metastatic colon cancer treatment. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2014 , 140, 881-2	3.9	7

20	Aberrant IKK α and IKK β cooperatively activate NF- κ B and induce EGFR/AP1 signaling to promote survival and migration of head and neck cancer. <i>Oncogene</i> , 2014 , 33, 1135-47	9.2	67
19	Emerging insights into head and neck cancer metastasis. <i>Head and Neck</i> , 2013 , 35, 1669-78	4.2	37
18	Clinical assessment and treatment of the dysfunctional larynx after radiation. <i>Otolaryngology - Head and Neck Surgery</i> , 2013 , 149, 830-9	5.5	11
17	Endoscopic keel placement to treat and prevent anterior glottic webs. <i>Annals of Otology, Rhinology and Laryngology</i> , 2013 , 122, 672-8	2.1	18
16	Prevalence of diabetes mellitus and its impact on disease severity in adult recurrent respiratory papillomatosis. <i>Otolaryngology - Head and Neck Surgery</i> , 2013 , 149, 603-7	5.5	2
15	The clinical implications of antitumor immunity in head and neck cancer. <i>Laryngoscope</i> , 2012 , 122, 144-53.6	3.6	45
14	Comparative analysis of tumor-infiltrating lymphocytes in a syngeneic mouse model of oral cancer. <i>Otolaryngology - Head and Neck Surgery</i> , 2012 , 147, 493-500	5.5	36
13	Pathology quiz case 1. Primary diffuse large B-cell lymphoma of the larynx. <i>JAMA Otolaryngology</i> , 2011 , 137, 526, 528		2
12	TNF- α promotes c-REL/NF κ B interaction and TAp73 dissociation from key genes that mediate growth arrest and apoptosis in head and neck cancer. <i>Cancer Research</i> , 2011 , 71, 6867-77	10.1	59
11	NF κ B3 versatilely regulates a Broad NF- κ B gene program and promotes squamous epithelial proliferation, migration, and inflammation. <i>Cancer Research</i> , 2011 , 71, 3688-700	10.1	103
10	Pathology quiz case 2. Lingual thyroid. <i>JAMA Otolaryngology</i> , 2010 , 136, 311, 313-4		
9	Molecular and clinical responses in a pilot study of gefitinib with paclitaxel and radiation in locally advanced head-and-neck cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010 , 77, 447-54	4	30
8	Human papillomavirus and oropharynx cancer: biology, detection and clinical implications. <i>Laryngoscope</i> , 2010 , 120, 1756-72	3.6	128
7	Proteomic signatures of epidermal growth factor receptor and survival signal pathways correspond to gefitinib sensitivity in head and neck cancer. <i>Clinical Cancer Research</i> , 2009 , 15, 2361-72	12.9	50
6	Bortezomib-induced apoptosis with limited clinical response is accompanied by inhibition of canonical but not alternative nuclear factor- κ B subunits in head and neck cancer. <i>Clinical Cancer Research</i> , 2008 , 14, 4175-85	12.9	63
5	Pulsed high-intensity focused ultrasound enhances apoptosis and growth inhibition of squamous cell carcinoma xenografts with proteasome inhibitor bortezomib. <i>Radiology</i> , 2008 , 248, 485-91	20.5	50
4	The p53 homologue DeltaNF κ B3 α interacts with the nuclear factor- κ B pathway to modulate epithelial cell growth. <i>Cancer Research</i> , 2008 , 68, 5122-31	10.1	40
3	Role of activated nuclear factor- κ B in the pathogenesis and therapy of squamous cell carcinoma of the head and neck. <i>Head and Neck</i> , 2007 , 29, 959-71	4.2	86

2	Nuclear factor-kappaB-related serum factors as longitudinal biomarkers of response and survival in advanced oropharyngeal carcinoma. <i>Clinical Cancer Research</i> , 2007 , 13, 3182-90	12.9	100
1	Squamous-cell carcinoma686-692		